A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato) amminedichloro(cyclohexylamine)platinum(IV)

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1247-1256

  Sova, Petr ^a   Mistr, Adolf ^a   Kroutil, Ales ^a   Semerád, Martin ^a   Chlubnová, Hana ^a   Hrusková, Veronika ^a   Chládková, Jirina ^b   Chládek, Jaroslav ^b  

^a R and D   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Pharmacokinetics; Platinum anti cancer drugs; Wistar rat

Indexed keywords

BIS(ACETATO)(1 ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM; LA 12; PLATINUM COMPLEX; SATRAPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; KIDNEY; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; URINARY EXCRETION;

ADMINISTRATION, ORAL; AMANTADINE; ANIMALS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; MALE; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 79959587210     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1411-0     Document Type: Article

References (27)

1. Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522-1534 (Pubitemid 28446332)
2. Kelland LR (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584
3. Choy H, Park C, Yao M (2008) Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 14:1633-1638 (Pubitemid 351469447)
4. Zak F, Turánek J, Kroutil A, Sova P, Mistr A, Poulová A, Mikolin P, Zak Z, Kasna A, Zaluska D, Neca J, Sindlerova L, Kozubik A (2004) Platinum (IV) complex with adamantylamine as non-leaving amine group: synthesis, characterization, and in vitro antitumour activity against the panel of cisplatin resistant cancer cell lines. J Med Chem 47:761-763
5. Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P et al (2005) High effectiveness of platinum( IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69:373-383 (Pubitemid 40094498)
6. Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M (2006) Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs 17:201-206
7. Roubalová E, Kvardová V, Hrstka R, Bořilová S, Michalová E, Dubská L, Múller P, Sova P, Vojtěšek B (2009) The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Invest New Drugs Jun 5 [Epub ahead of print]
8. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, Bossard GE, Higgins JD (1995) Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entreé into orally active platinum(IV) antitumor agents. Inorg Chem 34:1015-1021
9. McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR (1994) Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine- platinum(IV) (JM216) in vivo. Cancer Res 54:4118-4122
10. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B et al (1995) A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451-458
11. Turánek J, Kasná A, Záluská D, Neca J, Kvardová V, Knótigová P et al (2004) New platinum (IV) complex with adamantylamine ligand as a promising anticancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum (IV) complexes. Anti- Cancer Drugs 15:537-543 (Pubitemid 38736953)
12. Kaspárková J, Nováková O, Vrána O, Intini F, Natile G, Brabec V (2006) Molecular aspect of antitumor effects of a new platinum( IV) drug. Mol Pharmacol 70:1708-1719
13. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of Bis-acetato-ammine- dichloro-cyclohexylamine Platinum(IV): an orally active platinum drug. Cancer Res 53:2581-2586 (Pubitemid 23168026)
14. Michalke B (2010) Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J Trace Elem Med Biol 24:69-77
15. Galettis P, Carr JL, Paxton JW, McKeage MJ (1999) Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal At Spectrom 14:953-956
16. Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF (1995) Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J Pharm Biomed Anal 13:1493-1498 (Pubitemid 26026990)
17. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR (1996) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155-162 (Pubitemid 26132404)
18. Carr JL, Tingle MD, McKeage MJ (2002) Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 50:9-15 (Pubitemid 34743990)
19. Carr JL, Tingle MD, McKeage MJ (2006) Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol 57:483-490 (Pubitemid 43087591)
20. Bell DN, Liu JJ, Tingle MD, Rattel B, Meyer TU, McKeage MJ (2008) Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro. Clin Exp Pharmacol Physiol 35:1440-1446
21. Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR (1996) Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1857-1862 (Pubitemid 26270696)
22. Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA (2003) Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res 23:2757-2765 (Pubitemid 36969812)
23. Kurata T, Tamura T, Sasaki Y, Fujii H, Negoro S, Fukuoka M, Saijo N (2000) Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine- dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 30:377-384
24. Hanada K, Ninomiya K, Ogata H (2000) Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. J Pharm Pharmacol 52:1345-1353
25. Sova P, Chladek J, Zak F, Mistr A, Kroutil A, Semerad M, Slovak Z (2005) Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC- 6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum (IV)]. Int J Pharm 288:123-129 (Pubitemid 39656460)
26. Johnsson A, Bjórk H, Schútz A, Skárby T (1998) Sample handling for determination of free platinum in blood after cisplatin exposure. Cancer Chemother Pharmacol 41:248-251 (Pubitemid 28094050)
27. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24:1-10